Member Info for jupiternmars

http://tinyurl.com/k56vs2z Dr Miroslav Reljanovic, chief executive of Ergomed (LON:ERGO), says the company believes it can increase its share price further, which he claims is still undervalued even after a 20% rise over the last six months. Reljanovic believes the acquisition strategy, coupled with newsflow over the coming months, should help the stock to continue its journey north. Ergomed’s CEO says it’s hard to pin down the exact size of the potential market but says the market for oncology treatments in general is very large. The company floated on AIM in July last year, raising £11mln to fund its ambitious growth plans.

http://tinyurl.com/ohr3yu8

http://tinyurl.com/nzwba97 Patrick Walker, who has recently taken over as chief executive of Rightster (LON:RSTR), says the company’s focus is now on execution. He says he will carry on the vision set out by former CEO Charlie Muirhead, but the plan is to accelerate growth without spending as much cash. It comes as the online video distribution specialist confirmed plans for raise £5.3mln in a placing. It also revealed it made a pre-tax loss of £18.8mln in 2014, which was slightly smaller than the £19.3mln loss registered the year before.

http://tinyurl.com/ka2a6r3 Peter Shaw, chief executive of DP Poland (LON:DPP), says the goal this year is to roll out the pizza franchise in two or three cities in Poland. The Domino’s Pizza franchisee already has stores in Warsaw and Krakow but it is aiming to expand outside Poland’s largest two cities in 2015. Shaw says the strategy is a combination of profitability and expansion. The company’s share price was on the rise yesterday after it revealed like-for-like sales across its corporate and franchised outlets were 17% higher than last year’s January-March period.

http://tinyurl.com/khzbnps

http://tinyurl.com/k8vdx8u Antony Odell, chief executive of Tissue Regenix (LON:TRX), discusses the company’s commercialisation push for its advanced wound care product. Today, the AIM-listed group revealed it will be sharing the latest data on DermaPure with some of the industry’s leadingprofessionals at the Symposium for Advanced Wound Care’s spring meeting in the US. It follows the news of a ‘critical step’ towards regulatory sign-off for the start of clinical trials for Orthopure XT, a decellularised tendon device for the reconstruction of a torn anterior cruciate ligament – a career-threatening injury for footballers and other athletes.

http://tinyurl.com/khf7khe Matthew Walls, chief executive of Epistem (Lon:EHP), says distribution of its handheld TB diagnostic device in India paves the way for other distributor-based deals globally. Walls tells Proactive Investors the test market for TB will be worth US$2bln by 2020, and the biotechnology company’s signature Genedrive tool lends itself to testing all bacterial, viral, fungal and somatic mutations of the body. Described as 'breakthrough next generation technology' Genedrive is gathering more commercial exposure and Walls says more funds may be required over the next few months to accelerate the device’s push into the global marketplace.

http://tinyurl.com/o7ro9tm Peter George, chief executive of Clinigen (LON:CLIN), says the £225mln acquisition of competitor Idis gives it access to the US$2.2bln ethical unlicensed medicine market. Synergy savings of £2.5mln have been identified in the deal which makes the specialty pharma company the global leader in unlicensed medicines. George tells Proactive Investors profit will be driven through the gross profit line much faster than synergy savings. “This is about a growth plan not a cost savings plan. We want to hit the ground running and take the market by storm.” The deal achieves the second of Clinigen’s four strategic goals which include becoming global leader in both clinical trials supply and unlicensed medicines. George says Clinigen wants to grow its portfolio from five to ten products and improve its global footprint by looking at the Southern hemisphere.

http://tinyurl.com/msfgly7

http://tinyurl.com/p8wpcdr

http://tinyurl.com/nbq26es The chairman and chief executive of Galasys (LON:GLS) explain why they are excited about the company’s maiden full year results since its AIM listing and new 20% stakeholder Beijing Shiji. Chairman Kim Seng Teh and chief executive Sean Seah tells Proactiveinvestors that Shiji’s relationship with China’s online marketplace Alibaba Group presents collaboration opportunities.

http://tinyurl.com/k8z8v7z Scott Maybury, the chief executive of Private & Commercial Finance Group (LON:PCF), says securing the £10mln facility shows the consumer and small business lender has the backing of the government. In fact, Maybury says he only knows of two other asset finance companies that have also been rewarded. The company has agreed a £10mln, three-year loan facility with the commercial arm of the UK government’s economic development bank. The British Business Bank Investments’ facility takes PCF’s total lending headroom to £32.7mln, which it says is sufficient to fund anticipated growth in both its SME and consumer finance divisions.

http://tinyurl.com/oqh6yr9 John Aldersey-Williams, chief executive of SeaEnergy (LON:SEA), says the company will see ‘continuing steps’ towards making a ‘real profit’ over the next few years. He says demand has been strong despite the tough climate for oil and gas companies recently, while it is also looking at other sectors where the technology can be applied. The company, which provides software to the oil and gas industry, said revenues last year were £7.4mln, up from £5.1mln the year before, while the loss after tax widened to £2.5mln from £800,000. The company did however make an operating profit before non-recurring expenses of £151,000.

http://tinyurl.com/on3xt4r

http://tinyurl.com/nvnlxrp

http://www.proactiveinvestors.co.uk/companies/stocktube/3620/ceo-of-new-aim-entrant-redx-pharma-on-bucking-the-traditional-biotech-trend-3620.html

http://tinyurl.com/p7dveq2

http://tinyurl.com/qc6lghk

http://tinyurl.com/oy6zyme

http://tinyurl.com/kcfmecn